Burden of diseases in poor resource countries: meeting the challenges of combating HIV/AIDS, tuberculosis and malaria. Tanzania Health Research Bulletin
2005; 7: 179–184.
The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Frontiers in Pharmacology
2014; 4: 177.
Polypharmacy and combination therapy in the management of hypertension in elderly patients with co-morbid diabetes mellitus. Drugs & Aging
2010; 27: 871–883.
Dandara, C, et al.
Cytochrome P450 pharmacogenetics in African populations: implications for public health. Expert Opinion Drug Metabolism and Toxicology
2014; 10: 769–785.
Ware, RE, et al.
Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood
2002; 99: 10–14.
Ganesh, SK, et al.
Genetics and genomics for the prevention and treatment of cardiovascular disease: update a scientific statement from the American Heart Association. Circulation
2013; 128: 2813–2851.
Ross, CJ, et al.
Pharmacogenomics of serious adverse drug reactions in pediatric oncology. Journal of Population Therapeutics and Clinical Pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique
2011; 18: e134–e151.
Lynch, T, Price, A.
The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. American Family Physician
2007; 76: 391–396.
Lazarou, J, Pomeranz, BH, Corey, PN.
Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. The Journal of the American Medical Association
1998; 279: 1200–1205.
Gurwitz, JH, et al.
Incidence and preventability of adverse drug events in nursing homes. American Journal of Medicine
2000; 109: 87–94.
Dandara, C, et al.
Editorial (An idea whose time has come? An African foresight observatory on genomics medicine and data-intensive global science). Current Pharmacogenomics and Personalized Medicine
2012; 10: 7–15.
Masimirembwa, C, Dandara, C, Hasler, J.
Population diversity and pharmacogenomics in Africa (Chapter 43). In: Padmanabhan, S, ed. Handbook of Pharmacogenomics and Stratified Medicine. San Diego: Academic Press, 2014, pp. 971–998.
Kitzmiller, JP, et al.
Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others. Cleveland Clinic Journal of Medicine
2011; 78: 243–257.
Hansen, NT, Brunak, S, Altman, RB.
Generating genome-scale candidate gene lists for pharmacogenomics. Clinical Pharmacology and Therapeutics
2009; 86: 183–189.
Relling, M, Evans, W.
Pharmacogenomics in the clinic. Nature
2015; 526: 343–350.
Dunnenberger, HM, et al.
Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annual Review of Pharmacology and Toxicology
2015; 55: 89–106.
Niemi, M, et al.
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics
2004; 14: 429–440.
Kivisto, KT, Niemi, M.
Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharmaceutical Research
2007; 24: 239–247.
Ho, RH, et al.
Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenetics and Genomics
2007; 17: 647–656.
Navarro, A, et al.
microRNA expression profiles identify subtypes of mantle cell lymphoma with different clinicobiological characteristics. Clinical Cancer Research
2013; 19: 3121–3129.
Pharmacoepigenetics and pharmacoepigenomics. Pharmacogenomics
2008; 9: 1785–1786.
Pharmacogenomics failing to reach developing countries. The Pharmacogenomics Journal
2014; 15: 731–732.
Kampira, E, et al.
Mitochondrial DNA subhaplogroups L0a2 and L2a modify susceptibility to peripheral neuropathy in malawian adults on stavudine containing highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes
2013; 63: 647–652.
Mukonzo, JK, et al.
Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. BMC Infectious Diseases
2013; 13: 261.
Ngaimisi, E, et al.
Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations. PloS ONE
2013; 8: e67946.
Swart, M, et al.
High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients. Pharmacogenetics and Genomics
2013; 23: 415–427.
Dhoro, M, et al.
CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe. BMC Pharmacology and Toxicology
2015; 16: 4.
Ouattara, A, et al.
Designing malaria vaccines to circumvent antigen variability. Vaccine
2015; 33: 7506–7512.
Gadalla, NB, et al.
Prevalence of Plasmodium falciparum anti-malarial resistance-associated polymorphisms in pfcrt, pfmdr1 and pfnhe1 in Muheza, Tanzania, prior to introduction of artemisinin combination therapy. Malaria Journal
2015; 14: 129.
Zhang, W, et al.
Pharmacogenomic Discovery Delineating the Genetic Basis of Drug Response. Current Genetic Medicine Reports
2013; 1: 143–149.
Matimba, A, et al.
Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes. The Pharmacogenomics Journal
2013; 15: 433–447.
Wang, L, Weinshilboum, RM.
Pharmacogenomics: candidate gene identification, functional validation and mechanisms. Human Molecular Genetics
2008; 17: R174–R179.
Gamazon, ER, Huang, RS, Cox, NJ.
SCAN: a systems biology approach to pharmacogenomic discovery. Methods in Molecular Biology
2013; 1015: 213–224.
Karnes, JH, et al.
Using systems approaches to address challenges for clinical implementation of pharmacogenomics. Wiley Interdisciplinary Reviews Systems Biology and Medicine
2014; 6: 125–135.
SanGiovanni, JP, et al.
Application and interpretation of genome-wide association (GWA) studies for informing pharmacogenomic research – examples from the field of age-related macular degeneration. Current Molecular Medicine
2014; 14: 814–832.
Wang, B, et al.
Clinical evidence supporting pharmacogen omic biomarker testing provided in US Food and Drug Administration drug labels. JAMA Internal Medicine
2014; 174: 1938–1944.
Sirugo, G, et al.
Genetic studies of African populations: an overview on disease susceptibility and response to vaccines and therapeutics. Human Genetics
2008; 123: 557–598.
Masimirembwa, C, et al.
Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs. European Journal of Clinical Pharmacology
1996; 51: 117–122.
Sachs, J, Malaney, P.
The economic and social burden of malaria. Nature
2002; 415: 680–685.
Rendic, S, Guengerich, FP.
Update information on drug metabolism systems-2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters. Current Drug Metabolism
2010; 11: 4–84.
Bains, RK, et al.
Molecular diversity and population structure at the Cytochrome P450 3A5 gene in Africa. BMC Genetics
2013; 14: 34.
Alessandrini, M, et al.
Cytochrome P450 pharmacogenetics in African populations. Drug Metabolism Reviews
2013; 45: 253–275.
Arts, EJ, Hazuda, DJ.
HIV-1 antiretroviral drug therapy. Cold Spring Harbor Perspectives in Medicine
2012; 2: a007161.
Yimer, G, et al.
High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naive HIV patients from Ethiopia: a prospective cohort study. The Pharmacogenomics Journal
2012; 12: 499–506.
Klein, K, et al.
Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenetics and Genomics
2005; 15: 861–873.
Gounden, V, et al.
Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Research and Therapy
2010; 7: 32.
Nyakutira, C, et al.
High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. European Journal of Clinical Pharmacology
2008; 64: 357–365.
Maganda, BA, et al.
CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients. The Pharmacogenomics Journal
2016; 16: 88–95.
di Iulio, J, et al.
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenetics and Genomics
2009; 19: 300–309.
Puls, R, et al.
Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet (London, England)
2014; 383: 1474–1482.
Maimbo, M, et al.
CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans. European Journal of Clinical Pharmacology
2012; 68: 267–271.
Wennerholm, A, et al.
The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity. Clinical Pharmacology and Therapeutics
2002; 71: 77–88.
Sim, SC, Kacevska, M, Ingelman-Sundberg, M.
Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. The Pharmacogenomics Journal
2013; 13: 1–11.
Pharmacogenomics toward personalized tamoxifen therapy for breast cancer. Pharmacogenomics
2015; 16: 287–296.
Lisbeth, P, et al.
Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. European Journal of Clinical Pharmacology
2016; 72: 175–184.
Kirchheiner, J, Seeringer, A.
Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochimica et biophysica acta
2007; 1770: 489–494.
Fohner, A, et al.
Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes. Pharmacogenetics and Genomics
2013; 23: 403–414.
Cappuccio, FP, Miller, MA.
Cardiovascular disease and hypertension in sub-Saharan Africa: burden, risk and interventions. Internal and Emergency Medicine
2016; 11: 299–305.
Scott, SA, et al.
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clinical Pharmacology and Therapeutics
2011; 90: 328–332.
Wang, ZY, et al.
Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy. Therapeutics and Clinical Risk Management
2015; 11: 449–467.
Moaddeb, J, Haga, SB.
Pharmacogenetic testing: current evidence of clinical utility. Therapeutic Advances in Drug Safety
2013; 4: 155–169.
Natarajan, S, et al.
Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients. Pharmacological Reports
2013; 65: 1375–1382.
Schelleman, H, et al.
Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clinical Pharmacology and Therapeutics
2008; 84: 332–339.
Mitchell, C, Gregersen, N, Krause, A.
Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population. Pharmacogenomics
2011; 12: 953–963.
Aithal, GP, et al.
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet
1999; 353: 717–719.
Yin, T, Miyata, T.
Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 – rationale and perspectives. Thrombosis Research
2007; 120: 1–10.
Dang, MT, Hambleton, J, Kayser, SR.
The influence of ethnicity on warfarin dosage requirement. The Annals of Pharmacotherapy
2005; 39: 1008–1012.
Hu, M, Tomlinson, B.
Pharmacogenomics of lipid-lowering therapies. Pharmacogenomics
2013; 14: 981–995.
Gelissen, IC, Brown, AJ.
Predicting response to statins by pharmacogenetic testing. Pharmacogenomics
2012; 13: 1223–1225.
Canestaro, WJ, et al.
Statin pharmacogenomics: opportunities to improve patient outcomes and healthcare costs with genetic testing. Journal of Personalized Medicine
2012; 2: 158–174.
Au, A, et al.
The influence of OLR1 and PCSK9 gene polymorphisms on ischemic stroke: evidence from a meta-analysis. Scientific Reports
2015; 5: 18224.
Ancheta, IB, et al.
The association between KIF6 single nucleotide polymorphism rs20455 and serum lipids in Filipino-American Women. Nursing Research and Practice
2014; 2014: 328954.
Marwa, KJ, et al.
Cytochrome P450 single nucleotide polymorphisms in an indigenous Tanzanian population: a concern about the metabolism of artemisinin-based combinations. Malaria Journal
2014; 13: 420.
Arnaldo, P, et al.
Frequencies of cytochrome P450 2B6 and 2C8 allelic variants in the Mozambican population. Malaysian Journal of Medical Sciences
2013; 20: 13–23.
Kudzi, W, Dodoo, AN, Mills, JJ.
Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Medical Genetics
2009; 10: 124.
Paganotti, GM, et al.
Human genetic variation is associated with Plasmodium falciparum drug resistance. Journal of Infectious Disease 2011; 204: 1772–1778.
African variation at cytochrome P450 genes: evolutionary aspects and the implications for the treatment of infectious diseases. Evolution, Medicine, and Public Health
2013; 2013: 118–134.
Modell, B, Darlison, M.
Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization
2008; 86: 480–487.
Ndefo, UA, et al.
Pharmacological management of sickle cell disease. P & T: a Peer-reviewed Journal for Formulary Management
2008; 33: 238–243.
McAuley, CF, et al.
High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Kenya. Blood
2010; 116: 1663–1668.
Makani, J, et al.
Malaria in patients with sickle cell anemia: burden, risk factors, and outcome at the outpatient clinic and during hospitalization. Blood
2010; 115: 215–220.
Grosse, SD, et al.
Sickle cell disease in Africa: a neglected cause of early childhood mortality. American Journal of Preventive Medicine
2011; 41 (6 Suppl. 4): S398–S405.
Makani, J, et al.
Sickle cell disease: new opportunities and challenges in Africa. The Scientific World Journal
2013; 2013: 193252.
Okwi, AL, et al.
An up-date on the prevalence of sickle cell trait in Eastern and Western Uganda. BMC Blood Disorders
2010; 10: 5.
Charache, S, et al.
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. The New England Journal of Medicine
1995; 332: 1317–1322.
Pino, P, et al.
Effects of hydroxyurea on malaria, parasite growth and adhesion in experimental models. Parasite Immunology
2006; 28: 675–680.
Green, NS, Barral, S.
Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease. Pediatric Blood and Cancer
2011; 56: 177–181.
Wonkam, A, et al.
Association of variants at BCL11A and HBS1L-MYB with hemoglobin F and hospitalization rates among sickle cell patients in Cameroon. PLoS ONE
2014; 9: e92506.
Mtatiro, SN, et al.
Genome wide association study of fetal hemoglobin in sickle cell anemia in Tanzania. PLoS ONE
2014; 9: e111464.
Mtatiro, SN, et al.
Genetic association of fetal-hemoglobin levels in individuals with sickle cell disease in Tanzania maps to conserved regulatory elements within the MYB core enhancer. BMC Medical Genetics
2015; 16: 4.